Importance of individualized follow-up stratified by type of implanted device for patients post standard EVAR for Abdominal Aortic Aneurysm



Cohnert T., Siegl G., Koter S., Portugaller R*.

Department of Vascular Surgery, *Department of Neuro and Interventional Radiology, Graz Medical University, Graz, Austria

Introduction and Objective

Within the established method of endovascular aneurysm repair long-term results and device durability are problematic in some devices, with FDA warnings issued for AAA treatment using specific devices. For the Endologix AFX system component separation is a specific complication with the risk of acute AAA rupture.



Methods

All patients who underwent standard EVAR using an Endologix AFX system between October 2015 and September 2022 were actively recalled and underwent physical examination, plain abdominal X-ray and CT Angiography.

Results

Out of 556 patients with AAA-repair 233 patients underwent EVAR. The 2 component Endologix AFX™ stent graft was used in 26 patients. No intra- or perioperative mortality occurred. However, 11 patients (42%) died after median follow-up of 23 months (range 1-49 months), of these one patient post 49 months due to component dislocation and confirmed AAA rupture. 3 patients are lost to follow-up.

Median survival in the 12 patients alive is 54 months. In 4 patients the AAA is shrinking, in 4 patients stable but not shrinking, in 3 patients growing under surveillance (Fig. 3). Component separation was found in 1 patient (Fig. 1) treated successfully by relining 68 months post primary implantation. 15 of the 26 patients did not adhere to the given follow-up schedule and did not present for the appointments scheduled (Fig. 2).

Conclusions

Life-long follow-up post EVAR is important. Follow-up requires computed tomography controls if aneurysm growth is suspected or plain abdominal x-ray for component migration due to artefacts of the stent graft in magnetic resonance. A strategy needs to be developed to ensure that patients follow the appointments and radiographic controls. A device-specific follow-up plan is required as some implants show specific risks during long-term treatment. According implementation in AAA treatment guidelines should be considered.



